Jodi Daniel joins Crowell & Moring LLP

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JODI DANIEL joined the firm Crowell & Moring LLP as a partner in its Health Care Group.

Daniel is the former director of the Office of Policy in the Office of the National Coordinator for Health Information Technology at the Department of Health and Human Services. Daniel served for a decade as the director at the ONC and 15 years at HHS, where she worked on changes in health information privacy and health information technology.

As the first senior counsel for health information technology in the Office of the General Counsel of HHS, Daniel developed HHS’s foundational legal strategies and coordinated all legal advice regarding health IT for HHS.

“Jodi literally wrote the book—and all the rules— governing health information technology, including the complex HIPAA privacy and enforcement rules,” said John Brennan, Jr., chair of the firm’s Health Care Group. “Her experience in setting the regulatory framework and policies for both technology providers and adopters has supported innovation in areas including mobile health, remote devices and telehealth, and that insight will be of enormous value to our clients as they operate in this highly regulated space.”

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login